CSMD1 and gastric cancer: Another study discovered that miR-642b-3p acts as an oncomiR that promotes tumour progression in GC by repressing CSMD1 expression and inactivating the Smad signalling pathway, which could contribute to the development of potential therapies for GC treatment [75].